Search results

Note that we have a thread for this article: Brunel University London - Reactivation of herpesviruses in Chronic Fatigue Syndrome

The IOM criteria, which many studies, including DecodeME, use, doesn't require a flu-like feeling. From DecodeME: Edit: The criteria from the NICE 2021 guidelines doesn't require flu-like feelings either.

Distinct Symptom Clusters Reflect Pathophysiological Mechanisms in ME/CFS Habermann-Horstmeier, Lotte; Horstmeier, Lukas M. [Line breaks added] Introduction Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a severe multisystemic disease with a broad spectrum of symptoms. A...

I'm not sure I'm saying something different from you. All I meant was, for the specific phenomenom of PEM, with the characteristic delay and several days long crash which is weird and so far eludes explanation, it seems fairly likely to me that there's one specific process that causes this same...

I'm not at all confident enough to make any strong claims, but these are basically the vague ideas that float around in my head: Symptoms related to sickness response (similar to flu symptom mechanism) - Genetic studies pointing to brain (DecodeME, Zhang preprint on HEAL2 model), aligns with...

I contacted the authors who confirmed the figure was not correct, and I see that they've updated the figure:

Isn't this the comparison between groups: "to a greater degree in the intervention group (p = 0.01)."

Evaluation of an online patient education program for children and young people with ME/CFS and their parents within the BAYNET FOR MECFS Study Background: ME/CFS (Myalgic Encephalomyelitis/Chronic Fatigue Syndrome) poses challenges for affected children and...

Yeah, it's confusing. In other places, they refer to Carruthers. One refers to CCC, one cites ICC: [2] is ICC.

Yeah, I wouldn't expect there to be actually zero real difference between days because I expect exercise to do things to anyone, so would expect some skew in the raw p-values, though maybe not so much it passes correction. But I agree it seems very strange to have so many very significant...

I don't think this is correct. For example, if all the findings are actually null, which would result in a uniform distribution of p-values between 0 and 1, there's a good chance nothing will pass the FDR threshold. I verified with some quick code which output a minimum q-value of 0.31 if the...

I'd assume a log transformation before doing the standardization would be good so that the expression data isn't heavily skewed. https://www.researchgate.net/post/What-is-Log-transformation-and-why-do-we-do-it-in-gene-expression-analysis Edit: Spoke too soon, I looked at the methodology file...

BBC: 'I want my album to help people understand my ME' The album can be listened to on Spotify.

Interview with neuroimaging researcher Zack Shan "What my research now is, we have these brain MRI findings. Can we combine with smart sensors and biomarkers? Eventually, what we find can apply to a real patient without MRI data. Because, for research, we can collect rich phenotype data, and...

What's interesting to me is there being any effect at all. If they gave the mice the IgG and they grew longer hair, or if they put the IgG on a petunia and it turned more yellow, it'd still indicate something is different about the IgG. Maybe then you could isolate the specific antibodies. And...

In case it's helpful, a recent review talking about immunoadsorption studies: Autoantibody targeting therapies in post COVID syndrome and myalgic encephalomyelitis/chronic fatigue syndrome, 2025, Wohlrab et al Refs:

Could you elaborate? If they can convincingly show that it is specifically the IgG that causes a change (with IgG depleted control solutions and whatnot), then I would think there is something in the IgG having a toxic effect. Is it that part about isolating IgG, or is it that differences in...

From the above thread: Here's the justification for this trial, from that website, auto-translated, with line breaks added:

Thread for this drug in a different condition: Phase 2b program with sonlicromanol in patients with mitochondrial disease due to m.3243A>G mutation, 2025, Smeitink et al.

SON4PEM Study: Sonlicromanol in Post-COVID: A Randomized, Double-blind, Placebo-controlled, Phase II Trial Brief Summary The aim of this randomized, doube-blind, placebo-controlled, phase II trial, is to study the effect of sonlicromanol on fatigue in patiënt with post-COVID who experience...